 |
17 Diseases |  |
1 Trial |
|
1 Trial |  |
553 News |  |
| «1234567 |
- | Potiga (retigabine) / Bausch Health, GSK
Trial termination: Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures (clinicaltrials.gov) - Sep 4, 2013
P3, N=76, Terminated, Sponsor: GlaxoSmithKline
Recruiting --> Terminated; Registration of the medicine is no longer being pursued in South Korea, Taiwan or Vietnam
- | Potiga (retigabine) / Bausch Health, GSK
Enrollment change: A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (clinicaltrials.gov) - Aug 28, 2013
P3, N=37, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Terminated; Registration of the medicine is no longer being pursued in South Korea, Taiwan or Vietnam N=269 --> 37
- Potiga (retigabine) / Bausch Health, GSK
Enrollment change: Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects (clinicaltrials.gov) - Aug 28, 2013
P1, N=1, Completed, Sponsor: GlaxoSmithKline
N=269 --> 37 N=16 --> 1
- Potiga (retigabine) / Bausch Health, GSK
Trial suspension: Study in Pediatric Subjects With Epilepsy (clinicaltrials.gov) - Jul 31, 2013
P2, N=8, Suspended, Sponsor: GlaxoSmithKline
N=16 --> 1 Completed --> Suspended
- ||||| Potiga (retigabine) / Bausch Health, GSK
Enrollment closed: Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS) (clinicaltrials.gov) - Jun 12, 2013
P3, N=100, Active, not recruiting, Sponsor: GlaxoSmithKline
Completed --> Suspended Recruiting --> Active, not recruiting
- |||| Potiga (retigabine) / Bausch Health, GSK
Enrollment open: An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures (clinicaltrials.gov) - May 22, 2013
P4, N=100, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Potiga (retigabine) / Bausch Health, GSK
Trial termination: Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures (clinicaltrials.gov) - May 15, 2013
P4, N=6, Terminated, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Terminated; After reevaluation of the benefit: risk profile of ezogabine/retigabine, GSK does not believe the early adjunctive treatment study population is appropriate.
- Potiga (retigabine) / Bausch Health, GSK
Enrollment change: Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures (clinicaltrials.gov) - May 15, 2013
P4, N=6, Terminated, Sponsor: GlaxoSmithKline
Recruiting --> Terminated; After reevaluation of the benefit: risk profile of ezogabine/retigabine, GSK does not believe the early adjunctive treatment study population is appropriate. N=208 --> 6
- Potiga (retigabine) / Bausch Health, GSK, ezogabine (XEN496) / Xenon
New P3 trial: CERETI: Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study (clinicaltrials.gov) - Apr 2, 2013
P3, N=15, Recruiting, Sponsor: University Hospital of Mont-Godinne
- ||||||| Potiga (retigabine) / Bausch Health, GSK
Trial completion, Monotherapy: IR: Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures (clinicaltrials.gov) - Mar 13, 2013
P3, N=203, Completed, Sponsor: GlaxoSmithKline
N=208 --> 6 Active, not recruiting --> Completed
- Potiga (retigabine) / Bausch Health, GSK
Trial withdrawal: Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects (clinicaltrials.gov) - Mar 6, 2013
P1, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Potiga (retigabine) / Bausch Health, GSK
Enrollment change: Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects (clinicaltrials.gov) - Mar 6, 2013
P1, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Not yet recruiting --> Withdrawn N=24 --> 0
- ||| Potiga (retigabine) / Bausch Health, GSK
New P3 trial: A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (clinicaltrials.gov) - Jan 24, 2013
P3, N=37, Active, not recruiting, Sponsor: GlaxoSmithKline
- Potiga (retigabine) / Bausch Health, GSK
New P4 trial: Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures (clinicaltrials.gov) - Nov 1, 2012
P4, N=6, Terminated, Sponsor: GlaxoSmithKline
- Potiga (retigabine) / Bausch Health, GSK
Clinical: Trobalt™ Products Risk Survey (clinicaltrials.gov) - Oct 24, 2012
P=N/A, N=1, Active, not recruiting, Sponsor: GlaxoSmithKline
- Potiga (retigabine) / Bausch Health, GSK
Trial completion: Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304 (clinicaltrials.gov) - Oct 24, 2012
P=N/A, N=1, Completed, Sponsor: GlaxoSmithKline
N=24 --> 0 Active, not recruiting --> Completed
- Potiga (retigabine) / Bausch Health, GSK
New P1 trial: Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects (clinicaltrials.gov) - Sep 23, 2012
P1, N=0, Withdrawn, Sponsor: GlaxoSmithKline
- Potiga (retigabine) / Bausch Health, GSK
Trial completion: Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite (clinicaltrials.gov) - Sep 19, 2012
P1, N=8, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Completed
- Potiga (retigabine) / Bausch Health, GSK
New P3 trial: Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS (clinicaltrials.gov) - Aug 16, 2012
P3, N=4, Terminated, Sponsor: GlaxoSmithKline
- || Potiga (retigabine) / Bausch Health, GSK
New P3 trial: Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures (clinicaltrials.gov) - Jul 22, 2012
P3, N=76, Terminated, Sponsor: GlaxoSmithKline
- Potiga (retigabine) / Bausch Health, GSK
Trial completion: Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects (clinicaltrials.gov) - Jul 4, 2012
P1, N=1, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Recruiting --> Completed
- ||||| Potiga (retigabine) / Bausch Health, GSK
New P4 trial: An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures (clinicaltrials.gov) - May 28, 2012
P4, N=100, Recruiting, Sponsor: GlaxoSmithKline
- ||| Potiga (retigabine) / Bausch Health, GSK
Review: Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy (clinicaltrials.gov) - Apr 25, 2012
P=N/A, N=6498, Completed, Sponsor: GlaxoSmithKline
- | Potiga (retigabine) / Bausch Health, GSK
Trial completion: An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed (clinicaltrials.gov) - Apr 25, 2012
P1, N=30, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Active, not recruiting --> Completed
- | Potiga (retigabine) / Bausch Health, GSK
New P1 trial: An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed (clinicaltrials.gov) - Mar 14, 2012
P1, N=30, Completed, Sponsor: GlaxoSmithKline
- Potiga (retigabine) / Bausch Health, GSK
New P3 trial: Long-term Open-label Evaluation of Retigabine in Pediatric Subjects with Epilepsy (EUDRACT) - Mar 8, 2012
P3, N=0, , Sponsor: GlaxoSmithKline R&D Limited
- Potiga (retigabine) / Bausch Health, GSK
Trial initiation date: Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304 (clinicaltrials.gov) - Jan 19, 2012
P=N/A, N=1, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Initiation date: Apr 2011 --> Aug 2011
- Potiga (retigabine) / Bausch Health, GSK
New P2 trial: Study in Pediatric Subjects With Epilepsy (clinicaltrials.gov) - Dec 15, 2011
P2, N=8, Suspended, Sponsor: GlaxoSmithKline
- Potiga (retigabine) / Bausch Health, GSK
New P1 trial: Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite (clinicaltrials.gov) - Nov 27, 2011
P1, N=8, Completed, Sponsor: GlaxoSmithKline
- Potiga (retigabine) / Bausch Health, GSK
New P1 trial: Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects (clinicaltrials.gov) - Oct 27, 2011
P1, N=1, Completed, Sponsor: GlaxoSmithKline